JAK/TYK2
Day 4 was a half day closeout to the EULAR 2023 Congress. For me the big presentations were the late breaking abstracts, although there were other review and abstract sessions for those remaining.…
![](https://pbs.twimg.com/profile_images/1215290012490702848/mq73skc3.jpg)
1 year 1 month ago
An update on JAK inhibitors and cardiovascular risks
Dr. Antoni Chan ( @synovialjoints ) shares #EULAR23 developments on JAK/TYK2 inhibitors.
https://t.co/VovWE2OuXW https://t.co/QXKZLh5RuK
![](https://pbs.twimg.com/media/Fx3hsybWYAAwKRC.jpg)
![](https://pbs.twimg.com/profile_images/1248272740831735809/C0SA-iJf.jpg)
1 year 1 month ago
JaL1/TYK2 inhibitor vs Tofacitinib in #RA at #EULAR2023 phase 2. @RheumNow https://t.co/0F3JQ9dVMA
![](https://pbs.twimg.com/media/Fxsgjk-XwAATpab.jpg)
![](https://pbs.twimg.com/profile_images/1248272740831735809/C0SA-iJf.jpg)
1 year 1 month ago
Abstracts talking about #RA and JAKs and Biologic comparisons
Huge number of pts to analyze this aftrr the initial NEJM study. Abstract summary pics below
@RheumNow https://t.co/jl5S4fLq19
![](https://pbs.twimg.com/media/FxsgQ1pX0AE1YAT.jpg)